The role of sacubitril and/or valsartan in patient with heart failure (HF) is established.
Whether sacubitril and/or valsartan plays a role in improving outcomes in patients after ST …

Aims We aimed to investigate whether sacubitril–valsartan could further improve the
prognosis, cardiac function, and left ventricular (LV) remodelling in patients following acute …

Background: Angiotensin-converting enzyme inhibitors attenuate left ventricular (LV)
enlargement after acute myocardial infarction (AMI). Preclinical data suggest similar benefits …

Some randomized controlled trials have compared the effectiveness and safety outcomes
between early initiation of Sacubitril/Valsartan and angiotensin‐converting enzyme …

Background: infarction (AMI) can be reduced by the use of sacubitril/valsartan. However, the
therapeutic effects of sacubitril/valsartan in clinical settings are inconsistent. In this paper …

Objective To evaluate the effects of early administration of Sacubitril/Valsartan (Sac/Val) in
patients with ST-elevation myocardial infarction after primary percutaneous coronary …

Aim The win ratio can incorporate different types of outcomes and enhance statistical power,
making it a useful method for analysing composite outcomes in cardiovascular trials. The …

Methods The design, baseline characteristics, and primary results of this institutional review
board–approved trial are published. 1, 2 In brief, PARADISE-MI was a double-blind, active …

Importance Despite advances in cardiac care, patients remain at a high risk of death and the
development of heart failure (HF) following myocardial infarction (MI). These risks are …

Purpose Sacubitril/valsartan reduced heart failure (HF) admissions and cardiovascular
mortality in the PARADIGM-HF trial. However, real-life studies are scarce comparing daily …